Be Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Be Biopharma's estimated annual revenue is currently $18.6M per year.
- Be Biopharma's estimated revenue per employee is $155,000
- Be Biopharma's total funding is $264M.
Employee Data
- Be Biopharma has 120 Employees.
- Be Biopharma grew their employee count by -14% last year.
Be Biopharma's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | Co-founder & VP, Strategy & Operations | Reveal Email/Phone |
4 | VP Clinical Development Operations | Reveal Email/Phone |
5 | VP, Business Operations | Reveal Email/Phone |
6 | VP, External Manufacturing & Supply Chain | Reveal Email/Phone |
7 | Head Immunology | Reveal Email/Phone |
8 | SVP - Commercial and Franchise Strategy | Reveal Email/Phone |
9 | VP Non-Clinical Development | Reveal Email/Phone |
10 | SVP Clinical Development | Reveal Email/Phone |
Be Biopharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Be Biopharma?
Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
keywords:N/A$264M
Total Funding
120
Number of Employees
$18.6M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Be Biopharma News
Greenwald, however, is taking a long-term view, betting that interest in gene therapy research will be there once the downturn is over. The...
Be Biopharma, a Cambridge, MA-based developer of Engineered B Cell Medicines (BeCM), closed a $130m financing.
--(BUSINESS WIRE)--Be Biopharma (Be Bio), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM), today announced...
Be Biopharma, a Cambridge, MA-based company developing B cells as medicines, raised $52m in Series A financing. The round was led by Atlas Venture and RA Capital Management joined by Alta Partners, Longwood Fund and Takeda Ventures. The company plans to use the funds to precisely engineer B ce ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $24.1M | 120 | 25% | N/A |
#2 | $38.8M | 120 | N/A | N/A |
#3 | $18.6M | 120 | 3% | N/A |
#4 | $17.6M | 120 | 19% | $89M |
#5 | $30.4M | 121 | 21% | N/A |